IP Library › Patent Application 18171694
Patent Application
App. No. 18/171,694

TISSUE ORGANOIDS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/171,694
Abstract

Physiologically-tailored tissue organoids are disclosed for monitoring and treating diseases and improving an individual's health.

Claims (27)

1 - 28 . (canceled)

29 . A method of treating an individual in need thereof for a disease, disorder, or addiction, comprising:

contacting a tissue organoid to the individual, the tissue organoid comprising a population of genetically engineered cells comprising at least one recombinant gene encoding a therapeutic agent.

30 . The method of claim 29 , wherein the tissue organoid is biointegrated into the individual by grafting or surgical implantation.

31 . The method of claim 29 , wherein the disease or disorder is PKU or hemophilia, and

wherein the addiction is one or more of cocaine addiction, alcoholism, nicotine addiction, or amphetamine addiction.

32 - 49 . (canceled)

50 . The method of claim 29 , wherein the therapeutic agent is expressed constitutively or by induction with an inducer.

51 . The method of claim 29 , wherein the therapeutic agent comprises phenylalanine ammonia lyase (PAL).

52 . The method of claim 51 , wherein the therapeutic agent treats phenylketonuria (PKU) in the individual.

53 . The method of claim 29 , wherein the therapeutic agent comprises Factor VIII or Factor IX.

54 . The method of claim 53 , wherein the therapeutic agent is conjugated with albumin.

55 . The method of claim 54 , wherein the therapeutic agent treats hemophilia in the individual.

56 . The method of claim 29 , wherein the therapeutic agent comprises hBChE.

57 . The method of claim 56 , wherein the therapeutic agent treats cocaine addiction in the individual.

58 . The method of claim 29 , wherein the therapeutic agent comprises one or more of DkTx, VaTx, glucagon-like peptide 1 (GLP-1), a GLP-1 analog, a modified GLP-1 (mGLP1), and a mGLP1 analog.

59 . The method of claim 58 , wherein the therapeutic agent is inducible by alcohol.

60 . The method of claim 59 , wherein the therapeutic agent treats alcoholism in the individual.

61 . The method of claim 58 , wherein the therapeutic agent treats nicotine or amphetamine addiction in the individual.

62 . The method of claim 29 , wherein the therapeutic agent comprises PYY.

63 . The method of claim 62 , wherein the therapeutic agent treats obesity in the individual.

64 . The method of claim 62 , wherein the therapeutic agent causes decreased food seeking and consumption by the individual.

65 . A method of producing anti-aging effects in an individual in need thereof, comprising:

contacting a tissue organoid to the individual, the tissue organoid comprising a population of genetically engineered cells comprising at least one recombinant gene encoding a therapeutic agent, wherein the therapeutic agent comprises TIMP2 or an analog thereof.

66 . A method of treating an individual in need thereof for a disease, disorder, or addiction, comprising:

contacting a tissue organoid to the individual, the tissue organoid comprising a population of genetically engineered cells comprising at least one recombinant gene encoding a therapeutic agent, wherein expression of the therapeutic agent is inducible by an inducer; and

administering an inducer to the individual to induce expression of the therapeutic agent.